Two-Drug combo tested for tough thyroid cancer
NCT ID NCT02143726
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding everolimus to sorafenib works better than sorafenib alone for people with advanced Hurthle cell thyroid cancer that no longer responds to radioactive iodine. The study includes 35 participants and measures how long the cancer stays under control. The goal is to see if the combination can shrink tumors or slow growth, though it may also increase side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sorafenib and everolimus
What this could lead to
If successful, this could point toward a more effective drug combination for a rare and hard-to-treat thyroid cancer.
What could go wrong
This is a small, early-phase trial with only 35 participants, so results may not apply broadly. Adding everolimus could also cause more side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HURTHLE CELL THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Sleepy Hollow
Sleepy Hollow, New York, 10591, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
-
Mercy Health System
Janesville, Wisconsin, 53547, United States
-
Nebraska Methodist Hospital
Omaha, Nebraska, 68114, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Siouxland Regional Cancer Center
Sioux City, Iowa, 51101, United States
-
Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina, 28328, United States
-
Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina, 27534, United States
-
Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina, 28546, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
-
Wayne Memorial Hospital
Goldsboro, North Carolina, 27534, United States